Receptor tyrosine kinases (including HER2, IGF1R, and FGFR1) have previously been described as drivers of metastatic breast cancer phenotypes through aberrant activation of pro-migratory and pro-invasive signaling cascades in vitro. This evidence concerns the gene ERBB2 and breast carcinoma.